Protara Therapeutics
TARA
25 hedge funds and large institutions have $21.9M invested in Protara Therapeutics in 2018 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 6 increasing their positions, 2 reducing their positions, and 6 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 2
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
0% more ownership
Funds ownership: 1.26% → 1.27% (+0%)
2% less capital invested
Capital invested by funds: $22.4M → $21.9M (-$500K)
17% less funds holding
Funds holding: 30 → 25 (-5)
83% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$164K |
| 2 |
BFM
Boothbay Fund Management
New York
|
+$116K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$84.8K |
| 4 |
BlackRock
New York
|
+$62.2K |
| 5 |
DS
DRW Securities
Chicago,
Illinois
|
+$46.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$150K |
| 2 |
PI
Pharmstandard International
Luxembourg
|
-$140K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$45K |
| 4 |
VF
Virtu Financial
New York
|
-$37K |
| 5 |
ARTA
A.R.T. Advisors
New York
|
-$32K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
26
Citadel Advisors
Miami,
Florida
| – | -$45K | -452 | Closed |
|
|
VF
27
Virtu Financial
New York
| – | -$37K | -369 | Closed |
|
|
ARTA
28
A.R.T. Advisors
New York
| – | -$32K | -321 | Closed |
|
29
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$31K | -307 | Closed |
|
|
LWCFA
30
Loring Wolcott & Coolidge Fiduciary Advisors
Boston,
Massachusetts
| – | -$16K | -158 | Closed |
|
31
Morgan Stanley
New York
| – | -$1K | -10 | Closed |
|
TARA Hedge Fund Activity: Q2 2018 in Review
25 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Protara Therapeutics (TARA) for Q2 2018, worth a combined $21.9M — down 2.2% from $22.4M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of TARA and 1 opened new positions — a net loss of 5 holders — while 2 trimmed existing stakes and 6 added.
The largest buyer was Renaissance Technologies, adding an estimated $164K. The largest seller was Vanguard Group, cutting an estimated $150K.
- 25 institutional investors held Protara Therapeutics (TARA) as of Q2 2018, down from 30 in Q1 2018.
- Funds reported $21.9M of Protara Therapeutics stock for Q2 2018, down 2.2% quarter-over-quarter.
- 1 fund opened new Protara Therapeutics positions in Q2 2018 and 6 closed out, a net change of -5 holders.
- The largest Protara Therapeutics buyer in Q2 2018 was Renaissance Technologies, an estimated $164K added.
- The largest Protara Therapeutics seller in Q2 2018 was Vanguard Group, an estimated $150K sold.
Based on aggregated 13F filings for Q2 2018.